ISRCTN15704862
Completed
未知
Testing Radical prostatectomy in men with prostate cancer and oligoMetastases to the bone (TRoMbone): a randomised controlled feasibility trial
niversity of Oxford (UK)0 sites50 target enrollmentFebruary 5, 2016
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- ewly diagnosed oligometastatic prostate cancer (1-3 skeletal lesions
- Sponsor
- niversity of Oxford (UK)
- Enrollment
- 50
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Men under 75 years old with locally resectable, oligometastatic prostate cancer, and fit for radical prostatectomy
Exclusion Criteria
- •Current exclusion criteria as of 18/10/2017:
- •1\. Contraindications to radical prostatectomy
- •2\. Visceral metastases
- •3\. Prior radiotherapy to the abdomen/pelvis or to skeletal metastases
- •4\. Any systemic therapy of prostate cancer (including standard care) for 12 or more months
- •5\. Participation in another prostate cancer clinical trial
- •Previous exclusion criteria:
- •1\. Contraindications to radical prostatectomy
- •2\. Visceral metastases
- •3\. Prior radiotherapy to the abdomen/pelvis or to skeletal metastases
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
How common is bacteria in the urine of patients with urinary catheters after radical surgery on the prostate for prostate cancer and does it get cleared one week after removing the catheterACTRN12610000966099Mr Robert Davies100
Active, not recruiting
Phase 1
A Phase 1/2, Open-Label Study in Men with Prostate Cancer to Assess the Safety, Pharmacokinetics, and Testosterone-Lowering Efficacy of TAK-448, Administered as a 1 Month Depot, Including a Randomized Portion With a Group Administered LeuproreliProstate cancerMedDRA version: 12.1Level: LLTClassification code 10007113Term: Cancer of prostateEUCTR2009-017668-18-FRMillennium Pharmaceuticals, Inc.
Active, not recruiting
Not Applicable
Testing of a new drug in men with prostate cancer that may help lower testosterone levels.EUCTR2009-017668-18-BEMillennium Pharmaceuticals, Inc.123
Active, not recruiting
Not Applicable
Partial prostate Ablation versus Radical Treatment (PART): Comparing partial ablation of the prostate to treatment or removal of the whole prostate in men with localised cancer of one side of the prostate onlyProstate cancerCancerISRCTN17249875niversity of Oxford800
Active, not recruiting
Not Applicable
A Clinical Phase II Study in Patients with Prostate Cancer and Bone Metastases with KML001 (KOMINOX®) - KML001 in patients with prostate cancer and bone metastasesProstate Cancer MetastaticMedDRA version: 8.1Level: LLTClassification code 10036909Term: Prostate cancer metastaticEUCTR2006-005607-33-DEKOMINOX USA, Inc.